Efficacy and safety of bamlanivimab in patients with COVID-19: A systematic review and meta-analysis
Behnam Amani, Lida Khodavirdilou, Kourosh Rajabkhah, Vida Kardan Moghaddam, Arash Akbarzadeh, Bahman Amani
World Journal of Virology, doi:10.5501/wjv.v13.i1.88660
BACKGROUND Monoclonal antibodies (mAbs) have shown clinical benefits against coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several studies have reported the use of bamlanivimab as a promising treatment option for COVID-19.
AIM To synthesize the latest evidence for the efficacy and safety of bamlanivimab alone in the treatment of adult patients with COVID-19.
METHODS A literature search was conducted in PubMed, Cochrane Library, Web of Science, medRxiv, and Google Scholar using "SARS-CoV-2", "COVID-19", "LY-CoV555", and "Bamlanivimab" keywords up to January 25, 2023. The quality of included studies was assessed using the Cochrane bias tools. The Comprehensive Meta-Analysis software version 3.0 was used to analyze the data.
RESULTS A total of 30 studies involving 47368 patients were included. A significant Amani B et al. Bamlanivimab for COVID-19 WJV https://www.wjgnet.com
References
Alam, Mahmud, Aggarwal, Fathma, Mahi et al., Clinical Impact of the Early Use of Monoclonal Antibody LY-CoV555 (Bamlanivimab) on Mortality and Hospitalization Among Elderly Nursing Home Patients: A Multicenter Retrospective Study, Cureus,
doi:10.7759/cureus.14933Bariola, Mccreary, Wadas, Kip, Marroquin et al., Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection, Open Forum Infect Dis,
doi:10.1093/ofid/ofab254Beeraka, Sukocheva, Lukina, Liu, Development of antibody resistance in emerging mutant strains of SARS CoV-2: Impediment for COVID-19 vaccines, Rev Med Virol,
doi:10.1002/rmv.2346Boaventura, Macedo, Ribeiro, Jaconiano, Soares, Post-COVID-19 Condition: Where Are We Now?, Life,
doi:10.3390/life12040517Brock, Dagher, Wechsler, Lipe, Chaftari et al., Use of Bamlanivimab in Cancer Patients with Mild-to-Moderate COVID-19, Open Forum Infect Dis,
doi:10.1093/ofid/ofab466.741Bull-Otterson, Baca, Saydah, Boehmer, Adjei et al., Post-COVID conditions among adult COVID-19 survivors aged 18-64 and≥ 65 years-United States, March 2020-November 2021, MMWR Morb Mortal Wkly Rep,
doi:10.15585/mmwr.mm7121e1Center, Suite 160
Chen, Datta, Li, Chien, Price et al., First-in-Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID-19, Clin Pharmacol Ther,
doi:10.1002/cpt.2405Chen, Nirula, Heller, Gottlieb, Boscia et al., BLAZE-1 Investigators. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2029849Cheng, Reyes, Satram, Birch, Gibbons et al., Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA, Infect Dis Ther,
doi:10.1007/s40121-022-00755-0Chew, Moser, Daar, Wohl, Li et al., Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19, Nat Commun,
doi:10.1038/s41467-022-32551-2Choudhary, Chew, Deo, Flynn, Regan et al., ACTIV-2/A5401 Study Team. Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial, Nat Microbiol,
doi:10.1038/s41564-022-01254-1Cooper, Christensen, Salazar, Perez, Graviss et al., Real-world Assessment of 2879 COVID-19 Patients Treated With Monoclonal Antibody Therapy: A Propensity Score-Matched Cohort Study, Open Forum Infect Dis,
doi:10.1093/ofid/ofab512Corwin, Ender, Sahu, Durgham, Mcgorry et al., The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a Real-world Setting, Open Forum Infect Dis,
doi:10.1093/ofid/ofab305Cox, Peacock, Harvey, Hughes, Wright et al., SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies, Nat Rev Microbiol,
doi:10.1038/s41579-022-00809-7Destache, Aurit, Schmidt, Erkes, Tierney et al., Bamlanivimab use in mild-to-moderate COVID-19 disease: A matched cohort design, Pharmacotherapy,
doi:10.1002/phar.2613Djuric, Bogicevic, Pešić, Davidovic, Naumovic, MO659: First Experience of Bamlanivimab for Covid-19 Positive Haemodialysis Patients: A Case-Control Study, Nephrol Dial Transplant,
doi:10.1093/ndt/gfac077.019Dougan, Nirula, Azizad, Mocherla, Gottlieb et al., BLAZE-1 Investigators. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2102685Farcy, Dalley, Miro, Swalley, Sherman et al., A Comparison of SARS-COV-2 Neutralizing Antibody Therapies in High-Risk Patients with Mild to Moderate COVID-19 Disease at a Single Academic Hospital, J Emerg Med,
doi:10.1016/j.jemermed.2021.07.025Filippo, Crovetto, Bucek, Nahass, Milano et al., Comparative Efficacy of Early COVID-19 Monoclonal Antibody Therapies: A Retrospective Analysis, Open Forum Infect Dis,
doi:10.1093/ofid/ofac080Ganesh, Pawlowski, Horo, Arndt, Arndt et al., Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19, J Clin Invest
Ganesh, Philpot, Bierle, Anderson, Arndt et al., Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019, J Infect Dis,
doi:10.1093/infdis/jiab377Gottlieb, Nirula, Chen, Boscia, Heller et al., Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial, N Engl J Med,
doi:10.1056/NEJMoa2033130Heller, Henrici, Büttner, Leube, Treske et al., SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab, Int J Infect Dis,
doi:10.1016/j.ijid.2023.01.012Higgins, Altman, Gøtzsche, Jüni, Moher et al., The Cochrane Collaboration's tool for assessing risk of bias in randomised trials, BMJ,
doi:10.1136/bmj.d5928Hoffmann, Hofmann-Winkler, Krüger, Kempf, Nehlmeier et al., SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination, Cell Rep,
doi:10.1016/j.celrep.2021.109415Huang, Mccreary, Bariola, Minnier, Wadas et al., Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness Trial, JAMA Netw Open,
doi:10.1001/jamanetworkopen.2022.20957Iqbal, Terlau, Hernandez, Woods, Efficacy of Bamlanivimab in Reducing Hospitalization and Mortality Rates in COVID-19 Patients in a Rural Community, Cureus,
doi:10.7759/cureus.16477Kertes, Shapiro, David, Engel-Zohar, Rosen et al., Bamlanivimab for COVID-19 WJV
Kumar, Wu, Stosor, Moore, Achenbach et al., Real-World Experience of Bamlanivimab for Coronavirus Disease 2019 (COVID-19): A Case-Control Study, Clin Infect Dis,
doi:10.1093/cid/ciab305Lanzavecchia, Beyer, Bolo, Vaccination Is Not Enough: Understanding the Increase in Cases of COVID-19 in Chile despite a High Vaccination Rate, Epidemiologia,
doi:10.3390/epidemiologia2030028Lee, Lee, Lee, Kim, Lee et al., Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity score-matched retrospective cohort study, Int Immunopharmacol,
doi:10.1016/j.intimp.2022.108570Lin, Hung, Lai, Wang, Chen, The impact of neutralizing monoclonal antibodies on the outcomes of COVID-19 outpatients: A systematic review and meta-analysis of randomized controlled trials, J Med Virol,
doi:10.1002/jmv.27623Mccreary, Bariola, Minnier, Wadas, Shovel et al., A learning health system randomized trial of monoclonal antibodies for COVID-19,
doi:10.1101/2021.09.03.21262551Moher, Liberati, Tetzlaff, Altman, Group, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, PLoS Med,
doi:10.1371/journal.pmed.1000097Monday, Brar, Alangaden, Ramesh, SARS-CoV-2 neutralizing antibodies for COVID-19: Outcomes for bamlanivimab versus bamlanivimab-etesevimab combination in a racially diverse cohort of patients with significant comorbidities, J Clin Pharm Ther,
doi:10.1111/jcpt.13694Murillo, Lomiguen, Terrell, King, Lin et al., Effect of SARS CoV2-Neutralizing Monoclonal Antibody on Hospitalization and Mortality in Long-Term Care Facility Residents, Aging Dis,
doi:10.14336/AD.2022.0205Peiffer-Smadja, Bridier-Nahmias, Ferré, Charpentier, Garé et al., Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2, Viruses,
doi:10.3390/v13081642Priest, Blanchette, Hekman, Maddikunta, Burleson, Bamlanivimab for the Prevention of Hospitalizations and Emergency Department Visits in SARS-CoV-2-Positive Patients in a Regional Health Care System, Infect Dis Clin Pract
Quenzer, Lafree, Grey, Singh, Smyers et al., Bamlanivimab Reduces ED Returns and Hospitalizations and May Reduce COVID-19 Burden on Low-resource Border Hospitals, West J Emerg Med,
doi:10.5811/westjem.2021.10.52668Razonable, Pawlowski, Horo, Arndt, Arndt et al., Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19, EClinicalMedicine,
doi:10.1016/j.eclinm.2021.101102Rubin, Boiarsky, Canha, Giobbie-Hurder, Liu et al., Bamlanivimab Efficacy in Older and High-BMI Outpatients With COVID-19 Selected for Treatment in a Lottery-Based Allocation Process, Open Forum Infect Dis,
doi:10.1093/ofid/ofab546Savoldi, Morra, Nardo, Cattelan, Mirandola et al., Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study, Eur J Clin Microbiol Infect Dis,
doi:10.1007/s10096-022-04464-xSridhara, Gungor, Erol, Al-Obaidi, Zangeneh et al., Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA.2, BA.2.12.1 and BA.5 subvariants dominated era, PLoS One,
doi:10.1371/journal.pone.0279326Sterne, Hernán, Reeves, Savović, Berkman et al., ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions, BMJ,
doi:10.1136/bmj.i4919Sukocheva, Maksoud, Beeraka, Madhunapantula, Sinelnikov et al., Analysis of post COVID-19 condition and its overlap with myalgic encephalomyelitis/chronic fatigue syndrome, J Adv Res,
doi:10.1016/j.jare.2021.11.013Tao, Tzou, Pond, Ioannidis, Shafer, Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis, Microbiol Spectr,
doi:10.1128/spectrum.00926-22Taylor, Adams, Hufford, De La Torre, Winthrop et al., Neutralizing monoclonal antibodies for treatment of COVID-19, Nat Rev Immunol,
doi:10.1038/s41577-021-00542-xVena, Cenderello, Balletto, Mezzogori, Barbone et al., Early Administration of Bamlanivimab in Combination with Etesevimab Increases the Benefits of COVID-19 Treatment: Real-World Experience from the Liguria Region, J Clin Med,
doi:10.3390/jcm10204682Voelker, Jerath, Monoclonal antibody infusion for COVID-19 infection: results from a tertiary referral center, J Allergy Clin Immunol,
doi:10.1016/j.jaci.2021.12.639Webb, Buckel, Vento, Butler, Grisel et al., Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-19, Open Forum Infect Dis,
doi:10.1093/ofid/ofab331Xiang, He, Li, Cheng, Zhang et al., Bamlanivimab plus etesevimab treatment have a better outcome against COVID-19: A meta-analysis, J Med Virol,
doi:10.1002/jmv.27542Zuo, Ao, Wang, Gao, Qi, Bamlanivimab improves hospitalization and mortality rates in patients with COVID-19: A systematic review and meta-analysis, J Infect,
doi:10.1016/j.jinf.2021.09.003{ 'indexed': {'date-parts': [[2024, 3, 12]], 'date-time': '2024-03-12T00:26:41Z', 'timestamp': 1710203201522},
'reference-count': 56,
'publisher': 'Baishideng Publishing Group Inc.',
'issue': '1',
'content-domain': {'domain': [], 'crossmark-restriction': False},
'abstract': '<jats:p>BACKGROUND</jats:p>\n'
' <jats:p>Monoclonal antibodies (mAbs) have shown clinical benefits against '
'coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 '
'(SARS‑CoV‑2). Several studies have reported the use of bamlanivimab as a promising treatment '
'option for COVID-19.</jats:p>\n'
' <jats:p>AIM</jats:p>\n'
' <jats:p>To synthesize the latest evidence for the efficacy and safety of '
'bamlanivimab alone in the treatment of adult patients with COVID-19.</jats:p>\n'
' <jats:p>METHODS</jats:p>\n'
' <jats:p>A literature search was conducted in PubMed, Cochrane Library, Web of '
'Science, medRxiv, and Google Scholar using “SARS‑CoV‑2”, “COVID-19”, “LY-CoV555”, and '
'“Bamlanivimab” keywords up to January 25, 2023. The quality of included studies was assessed '
'using the Cochrane bias tools. The Comprehensive Meta-Analysis software version 3.0 was used '
'to analyze the data.</jats:p>\n'
' <jats:p>RESULTS</jats:p>\n'
' <jats:p>A total of 30 studies involving 47368 patients were included. A significant '
'difference was observed between the bamlanivimab and standard of care/placebo groups in terms '
'of mortality rate [risk ratio (RR) = 50, 95% confidence interval (CI): 0.36-0.70], '
'hospitalization rate (RR = 0.51; 95%CI: 0.39-0.68), and emergency department (ED) visits (RR '
'= 0.69; 95%CI: 0.47-0.99); while the two groups exhibited no significant difference in terms '
'of intensive care unit (ICU) admission (P > 0.05). Compared to other mAbs, bamlanivimab '
'was associated with a higher rate of hospitalization (RR = 1.44; 95%CI: 1.07-1.94). However, '
'no significant difference was detected between the bamlanivimab and other mAbs groups in '
'terms of mortality rate, ICU admission, and ED (P > 0.05). The incidence of any adverse '
'events was similar between the bamlanivimab and control groups (P > 0.05).</jats:p>\n'
' <jats:p>CONCLUSION</jats:p>\n'
' <jats:p>Although the results suggest the efficacy and safety of bamlanivimab in '
'COVID-19 patients, further research is required to confirm the efficacy of this drug for the '
'current circulating SARS-CoV-2 variants.</jats:p>',
'DOI': '10.5501/wjv.v13.i1.88660',
'type': 'journal-article',
'created': {'date-parts': [[2024, 3, 11]], 'date-time': '2024-03-11T08:54:45Z', 'timestamp': 1710147285000},
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Efficacy and safety of bamlanivimab in patients with COVID-19: A systematic review and '
'meta-analysis',
'prefix': '10.5501',
'volume': '13',
'author': [ {'given': 'Behnam', 'family': 'Amani', 'sequence': 'first', 'affiliation': []},
{'given': 'Lida', 'family': 'Khodavirdilou', 'sequence': 'additional', 'affiliation': []},
{'given': 'Kourosh', 'family': 'Rajabkhah', 'sequence': 'additional', 'affiliation': []},
{'given': 'Vida', 'family': 'Kardan Moghaddam', 'sequence': 'additional', 'affiliation': []},
{'given': 'Arash', 'family': 'Akbarzadeh', 'sequence': 'additional', 'affiliation': []},
{'given': 'Bahman', 'family': 'Amani', 'sequence': 'additional', 'affiliation': []}],
'member': '2060',
'published-online': {'date-parts': [[2024, 3, 25]]},
'reference': [ {'key': 'B1', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/epidemiologia2030028'},
{'key': 'B2', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/molecules27238562'},
{'key': 'B3', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jamanetworkopen.2022.20957'},
{'key': 'B4', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.eclinm.2021.101102'},
{'key': 'B5', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/cid/ciac625'},
{'key': 'B6', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.intimp.2022.108570'},
{'key': 'B7', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/jcm10204682'},
{'key': 'B8', 'doi-asserted-by': 'publisher', 'DOI': '10.7759/cureus.16477'},
{'key': 'B9', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41577-021-00542-x'},
{'key': 'B10', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/milmed/usab188'},
{'key': 'B11', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jemermed.2021.07.025'},
{'key': 'B12', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2102685'},
{'key': 'B13', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/ofid/ofab254'},
{'key': 'B14', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/phar.2613'},
{'key': 'B15', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/spectrum.00926-22'},
{'key': 'B16', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.pmed.1000097'},
{'key': 'B17', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmj.i4919'},
{'key': 'B18', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmj.d5928'},
{'key': 'B19', 'doi-asserted-by': 'publisher', 'DOI': '10.7759/cureus.14933'},
{'key': 'B20', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/ofid/ofab466.741'},
{'key': 'B21', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/cpt.2405'},
{'key': 'B22', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2029849'},
{'key': 'B23', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41467-022-32551-2'},
{'key': 'B24', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/ofid/ofab512'},
{'key': 'B25', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/ofid/ofab305'},
{'key': 'B26', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/ndt/gfac077.019'},
{'key': 'B27', 'doi-asserted-by': 'publisher', 'DOI': '10.1172/JCI151697'},
{'key': 'B28', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/infdis/jiab377'},
{'key': 'B29', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2021.0202'},
{'key': 'B30', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2033130'},
{'key': 'B31', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijid.2023.01.012'},
{'key': 'B32', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/cid/ciab305'},
{'key': 'B33', 'doi-asserted-by': 'publisher', 'DOI': '10.1101/2021.09.03.21262551'},
{'key': 'B34', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/jcpt.13694'},
{'key': 'B35', 'doi-asserted-by': 'publisher', 'DOI': '10.14336/AD.2022.0205'},
{ 'key': 'B36',
'doi-asserted-by': 'crossref',
'unstructured': 'Priest DH, Blanchette LM, Hekman AL, Maddikunta R, Burleson PE. '
'Bamlanivimab for the Prevention of Hospitalizations and Emergency '
'Department Visits in SARS-CoV-2-Positive Patients in a Regional Health '
'Care System. Infect Dis Clin Pract 2022; 30: 1-4',
'DOI': '10.1097/IPC.0000000000001130'},
{'key': 'B37', 'doi-asserted-by': 'publisher', 'DOI': '10.5811/westjem.2021.10.52668'},
{'key': 'B38', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/ofid/ofab546'},
{'key': 'B39', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/ofid/ofac080'},
{'key': 'B40', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s10096-022-04464-x'},
{'key': 'B41', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.pone.0279326'},
{'key': 'B42', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jaci.2021.12.639'},
{'key': 'B43', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/ofid/ofab331'},
{'key': 'B44', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s41232-022-00233-7'},
{'key': 'B45', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jmv.27542'},
{'key': 'B46', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jinf.2021.09.003'},
{'key': 'B47', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s40121-022-00755-0'},
{'key': 'B48', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41579-022-00809-7'},
{'key': 'B49', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jmv.27623'},
{'key': 'B50', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/life12040517'},
{'key': 'B51', 'doi-asserted-by': 'publisher', 'DOI': '10.15585/mmwr.mm7121e1'},
{'key': 'B52', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jare.2021.11.013'},
{'key': 'B53', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.celrep.2021.109415'},
{'key': 'B54', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/v13081642'},
{'key': 'B55', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41564-022-01254-1'},
{'key': 'B56', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/rmv.2346'}],
'container-title': 'World Journal of Virology',
'original-title': [],
'link': [ { 'URL': 'https://www.wjgnet.com/2220-3249/full/v13/i1/88660.htm',
'content-type': 'text/html',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://www.wjgnet.com/2220-3249/full/v13/i1/88660.htm',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2024, 3, 11]],
'date-time': '2024-03-11T08:55:27Z',
'timestamp': 1710147327000},
'score': 1,
'resource': {'primary': {'URL': 'https://www.wjgnet.com/2220-3249/full/v13/i1/88660.htm'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2024, 3, 25]]},
'references-count': 56,
'journal-issue': {'issue': '1'},
'alternative-id': ['88660'],
'URL': 'http://dx.doi.org/10.5501/wjv.v13.i1.88660',
'relation': {},
'ISSN': ['2220-3249'],
'subject': [],
'container-title-short': 'World J Virol',
'published': {'date-parts': [[2024, 3, 25]]}}
